Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fonc.2021.691002.s001BackgroundThe lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association between pretreatment LIPI score and therapeutic outcomes in cancer patients treated with ICIs.MethodsWe searched PubMed, Cochrane Library literature databases and EMBASE for abstracts and full-text articles published from the inception of the database until 16th, Nov 2020. Meta-analyses were performed separately for progression-free survival (PFS) and overall survival (OS) by using the random-effects model.ResultsA total of 12 studies involving 4883 patients receiving ICIs treatment were identified for the primary analysis. The pooled results implied that compared with good LIPI score groups, patients with poor or intermediate LIPI score were significantly associated with worse OS (HR=3.33, 95%CI 2.64-4.21, P 2 = 64.2%; HR=1.71, 95%CI 1.43-2.04, P 2 = 43.6%, respectively) and PFS (HR=2.73,95%CI 2.00-3.73, P 2 = 78.2%; HR=1.43, 95%CI 1.28-1.61, P 2 = 16.3%, respectively). Also, for 1873 patients receiving chemotherapy, a poor LIPI score was significantly associated with worse OS (HR=2.30, 95%CI 1.73-3.07, P 2 = 56.2%) and PFS (HR=1.92,95%CI 1.69-2.17; P 2 = 0.0%) compared with good LIPI score groups.ConclusionsA good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the types of cancer.
Keyword(s):
Cancer; Cancer Cell Biology; Cancer Diagnosis; Cancer Genetics; Cancer Therapy (excl. Chemotherapy and Radiation Therapy).
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)